Tadalafil

Cialis treats adult male ED, BPH signs/symptoms, or both. When used with finasteride to initiate BPH treatment, the Cialis contribution is recommended for up to 26 weeks because benefit beyond that is unknown. Adcirca and Tadliq treat WHO group 1 PAH to improve exercise ability; label evidence primarily involved functional class II–III idiopathic/heritable or connective-tissue-associated PAH. These labels do not authorize routine use for every form of pulmonary hypertension.

ED benefit needs sexual stimulation and is not contraception or STI protection. Cialis BPH evaluation must consider other urinary causes and coexisting prostate cancer. PAH therapy requires a specialist treatment plan; this profile does not supply a complete PAH combination-treatment algorithm or an off-label pediatric regimen. Do not combine tadalafil brands or other PDE5 inhibitors.

Selected products can be taken with or without food. Lower limits apply with organ impairment or interactions.

ED as needed with Child-Pugh A/B: do not exceed 10 mg once/day; caution because repeated daily exposure is less studied. Daily ED/BPH with A/B: limited evidence, use caution; Child-Pugh C: Cialis not recommended. PAH with A/B cirrhosis: consider starting 20 mg daily (Tadliq 5 mL); with C, avoid. Assess interacting-drug limits separately; these are not interchangeable organ algorithms.

ED/BPH with potent CYP3A4 inhibitors such as ketoconazole or ritonavir: as-needed maximum 10 mg every 72 hours; daily maximum 2.5 mg. PAH: avoid potent inhibitors such as ketoconazole/itraconazole; ritonavir has a separate timed protocol. If ritonavir has been used for ≥ 1 week, start PAH tadalafil 20 mg daily, then increase to 40 mg by tolerance. If initiating ritonavir in a patient on PAH tadalafil, stop tadalafil ≥ 24 hours before ritonavir; avoid during initiation, then after ≥ 1 week resume 20 mg daily and increase by tolerance. Use clinician supervision; do not copy the ED ritonavir rule into PAH.

Organic nitrates in any form, used regularly or intermittently; guanylate-cyclase stimulators such as riociguat; known serious hypersensitivity to tadalafil or product ingredients. Nitrates include nitroglycerin, isosorbide drugs and recreational nitrite/nitrate “poppers.” PAH labels expressly prohibit nitrates within 48 hours of the last dose. Severe organ impairment restrictions and cardiovascular cautions are additionally described in dosing/warnings rather than recast as universal section 4 contraindications.

The selected current U.S. labels have no boxed warning. Nitrate/riociguat contraindications, serious hypotension and urgent eye/hearing/priapism risks remain central to safe use.

Common ED/BPH effects include headache, dyspepsia, back pain, myalgia, congestion and flushing; PAH trials also report limb pain, nausea and respiratory symptoms. Rates differ by dose/indication and cannot be transferred between ED and PAH. Serious allergy/skin reactions, cardiovascular events, NAION and hearing loss are reported after marketing, with uncertain frequency or causality. Overdose requires urgent clinical/Poison Help assessment (U.S. 1-800-222-1222) and supportive care; dialysis removes tadalafil negligibly. PAH doses > 40 mg were not studied in the selected label.

Tadalafil is predominantly a CYP3A substrate; it is not expected to substantially inhibit or induce major CYP pathways. Selected studies did not show a clinically significant PK effect on warfarin or digoxin; this does not remove patient-specific bleeding, cardiac or polypharmacy assessment.

Cialis is not indicated in females. PAH labels describe limited pregnancy case-series data without an identified major-birth-defect/miscarriage signal; this is not proof of safety. Untreated maternal PAH itself risks HF, stroke, premature delivery and maternal/fetal death; specialist benefit/risk review is essential. Human milk/infant data are absent, with animal milk transfer; discuss breastfeeding and maternal need. Some long-exposure male studies found lower sperm concentrations of uncertain clinical significance; tadalafil is not a contraceptive.

Cialis is not indicated below 18 and its pediatric efficacy/safety is not established. U.S. Adcirca/Tadliq labels also do not establish pediatric safety/effectiveness; no pediatric dose is provided here. No age-only dose adjustment is required in selected adult labels, but older adults may be more sensitive and need review of renal function, BP and interacting medicines.

Kidney impairment increases exposure, and dialysis does not meaningfully clear the drug. Daily ED/BPH and PAH restrictions differ from intermittent ED dosing; follow the explicit table. Hepatic evidence mainly studied 10 mg in Child-Pugh A/B and is limited for higher/chronic exposure. Avoid or do not recommend severe impairment as the respective labels specify; combine organ and interaction assessments rather than applying one universal reduction.

Tadalafil inhibits PDE5-mediated cGMP breakdown. With sexual stimulation, this enhances penile smooth-muscle relaxation and blood flow; without stimulation it does not itself initiate erection. In PAH, increased pulmonary vascular cGMP promotes vasodilation. PDE5 is also present in lower urinary tract tissues, but the exact BPH symptom mechanism is not established.

Absorption

Food does not meaningfully alter exposure; peak timing varies. ED label median peak ~2 hours, PAH tablet label median ~4 hours.

Distribution / metabolism

~94% protein bound; predominant hepatic CYP3A metabolism, with metabolites not expected to be active at observed levels.

Half-life

ED label healthy-subject mean ~17.5 hours. PAH label after 40 mg: ~15 hours in healthy subjects, ~35 hours in pulmonary-hypertension patients not receiving bosentan. These are study-specific, not contradictory universal values.

Elimination / repeated use

Mostly metabolites in feces (~61%) and urine (~36%); steady state around 5 days. Dialysis has negligible removal.

Before ED therapy assess cardiovascular suitability for sex, nitrates/riociguat, BP, other vasodilators, renal/hepatic function and interacting drugs. Reassess ED response or BPH symptoms and alternate urinary causes. PAH follow-up needs specialist assessment of exercise/symptoms, disease progression, BP, tolerability and pulmonary edema/PVOD concern. New syncope, chest pain, eye/hearing changes or prolonged erection need immediate assessment; no routine plasma tadalafil concentration target is supplied.

Confirm the indication, schedule and exact product; do not add an extra ED dose to PAH treatment or a daily regimen. Avoid nitrates, poppers and riociguat and disclose the last dose during emergencies. Discuss all medicines, supplements, alcohol and organ disease before changes. ED treatment requires stimulation and gives no STI protection. Tadliq: shake 30 seconds before measuring and confirm 20 mg/5 mL; use an accurate oral device. Do not stop or alter PAH therapy without the specialist’s plan.

Cialis 5 mg: yellow almond-shaped film-coated tablet marked C 5; example 30-count bottle NDC 0002-4462-30. Appearance and supplied strengths differ among generics; use the actual label and package rather than color to identify a medicine.

Cialis and Adcirca: 25°C, permitted excursions 15–30°C. Reviewed Amneal tablets: 20–25°C, excursions 15–30°C. Tadliq: 20–25°C, excursions 15–30°C; dispense in a tight container and shake well for 30 seconds before use. Keep away from children and use the exact expiry/package instructions; the selected Tadliq label does not supply a universal post-opening discard interval.